Infections in the Immunocompromised Host

M. Cristina Vazquez-Guillamet, Joshua J. Mooney, and Joe L. Hsu

BACKGROUND

Recent decades have challenged the emergency physician to manage an evolving spectrum of infections in immune-compromised patients. This comes as a result of an increased use of immune suppression and infectious disease prophylaxis, as well as the improved survival of patients with human immunodeficiency virus (HIV), cancer, and following solid organ transplant (SOT) and hematopoietic stem cell transplantation (HSCT). Early diagnosis and treatment of these individuals with appropriate antimicrobial agents are essential for successful clinical outcomes.

DIAGNOSTIC EVALUATION

The frequent absence of early signs and symptoms traditionally used to define infection presents a major challenge in the care of immune-compromised patients. Cultures—the gold standard for guiding choice of antimicrobial agents—are positive in <50% of patients with invasive fungal diseases (IFDs) or febrile neutropenia and take several days for detection.^1,2 This diagnostic uncertainty is particularly concerning since delay in starting appropriate antimicrobial therapy is well established as a cause of increased mortality.³

When performing a targeted evaluation of an immune-compromised patient, the emergency physician should begin with an assessment of the “net state of immune suppression,” including an evaluation of the type of immune suppression, current immune suppressive therapy, level of immune suppression (myeloablative vs. nonmyeloablative regimen prior to HSCT, ongoing immune suppressive therapy), duration (transplant date, last chemotherapy, time from diagnosis of underlying malignancy), and anti-infective prophylaxis. Immune-suppressed patients will typically have unique pathogen susceptibilities based on their underlying immune defect (e.g., defects in T and/or B cells, neutropenia). A thorough patient history should document recent infections, including multidrug-resistant infections (MDRIs), latent and opportunistic infections, and recent surgical procedures including indwelling central venous catheters (CVC). In the patients with HIV, knowledge of a recent CD4 cell count and the use or lack of use of antiretroviral therapy (ART) and anti-infective prophylaxis is essential. The immune-compromised patient may have multiple potential infectious sources including donor acquired, nosocomial, reactivation, and environmental, and community acquired, all of which should be investigated.

In addition to standard infectious laboratory testing, non–culture-based methods including polymerase chain reaction (PCR) assays, antigen and antibody capture assays (Aspergillus galactomannan [GM], (1–3)-β-d-glucan, direct fluorescent antibody [DFA] stains), and microscopy with special stains, if available, should be ordered in consultation with infectious disease. Early use of computed tomography (CT) to identify an infectious source is also indicated since plain radiographs are known to lack sensitivity in the detection of infections in immune-suppressed patients.^4–8

INFECTIONS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS

The mortality of critically ill HIV-infected patients has decreased to the point that survival rates now approach those seen in non-HIV patients.^9,10 Although survival in critically ill patients is independent of ART at the time of admission, the use of ART is associated with higher CD4 counts, increased virologic suppression, and lower rates of opportunistic infections (such as Pneumocystis jirovecii pneumonia [PJP] and others) that independently correlate with survival.¹¹ These changes have shifted the epidemiology of critically ill HIV-infected patients beyond opportunistic infections to include nosocomial and community-acquired infections, comorbid chronic diseases, and medication-related toxicities, including the immune reconstitution inflammatory syndrome (IRIS).¹² In general, ART should be continued in critically ill HIV-infected patients with known prior virologic suppression; at the same time, these patients should be monitored for drug side effects (although rare, nucleoside analog reverse transcriptase inhibitors can cause lactic acidosis), proper dosing, and pharmacologic interactions.¹³

Sepsis in HIV-Positive Patients

The incidence of sepsis in ICU admissions of HIV-infected patients increased from 12% in 1995 to 20% in 2000, but mortality continues to improve.^11,14 More than half of these septic episodes were due to respiratory infections, followed by bacteremia, catheter-related blood stream infections (CRBSIs), and urinary tract infections (UTIs). Nosocomial pathogens, including Staphylococcus aureus and Pseudomonas aeruginosa, were the organisms implicated in up to 60% of all infections, followed by opportunistic and community-acquired pathogens.¹⁵ Sepsis-associated mortality among HIV-infected patients is correlated to illness severity, rather than degree of immune deficiency; however, an increased risk of nosocomial and opportunistic pathogen infection is observed with CD4 cell counts <200 cells/mm³ and with the absence of ART.¹⁵

Treatment of Infection in the HIV-Positive Patient

Treatment of infection in any immune-compromised patient includes goal-directed therapy and broad-spectrum antimicrobials, including empiric coverage for nosocomial organisms in patients at risk for severe sepsis. In HIV-infected patients with suspected sepsis and recent initiation of ART, the possibility of IRIS should be considered. IRIS presents as either a localized or systemic inflammatory reaction that develops after initiation of ART (typically 90 d later) and is due to recovery of the patient’s immune response. The syndrome results from either the inflammatory reaction to a recognized preexisting infection (e.g., Pneumocystis jirovecii) or the unmasking of an unrecognized preexisting infection (e.g., Mycobacterium avium complex [MAC], Mycobacterium tuberculosis [MTB], endemic fungal infections) with clinical features related to the prior infection. The diagnosis is one of exclusion. Active infection and drug reaction (e.g., abacavir hypersensitivity) must first be excluded. Management of IRIS is supportive, with continued treatment of the underlying infection and ART. In moderate to severe cases of IRIS, the use of prednisone (1 mg/kg/d) has been employed, although no controlled trials definitively support its benefit.

Respiratory Infections in HIV-Positive Patients

Respiratory infections are the most common reason HIV-infected patients are admitted to the ICU. The clinical presentation, radiographic appearance, and CD4 count help narrow the differential diagnosis (Table 34.1). Streptococcus pneumoniae is the most common etiologic agent.³⁵ Risk factors for MDRIs include CD4 cell counts <200 cells/mm³, underlying lung disease, neutropenia, and recent health care exposures.¹⁵

The incidence of PJP has declined with the use of prophylactic antibiotics and ART, but it remains the most common opportunistic respiratory infection and should be considered in those with a CD4 cell count <200 cells/mm³. The sputum immunofluorescent antibody (IFA) test, the presence of ground-glass opacities on high-resolution chest CT scan, and/or elevated serum (1,3)-β-d-glucan³⁶ are reliable noninvasive tests for diagnosing PJP.^19,20,22 All patients should undergo arterial blood gas (ABG) sampling on ambient air to determine if adjunct corticosteroids (typically prednisone 40 mg q12h) and low tidal volume ventilation (employed in mechanically ventilated patients to minimize the risk for pneumothorax) are indicated. A PaO₂ < 70 mm Hg on ABG or an alveolar–arterial difference (A-a gradient) of >35 mm Hg is the standard cutoff used for corticosteroid initiation.³⁷

HIV-infected patients are also at an increased risk of primary and reactivation of MTB infection. Those with a clinical syndrome suggestive of MTB should be placed in respiratory isolation, and three serial acid-fast bacillus (AFB) sputum samples should be collected. Common radiographic patterns of MTB include upper lung cavitation at higher CD4 cell counts and middle-to-lower lobe infiltrates at lower CD4 cell counts, but any radiographic pattern may be encountered. Severely immune-compromised HIV-infected patients (CD4 cell count <50 to 100 cells/mm³) are also at risk for pulmonary infections from endemic (e.g., Histoplasma capsulatum, Coccidioides immitis) and geographic (e.g., Cryptococcus neoformans) fungi and M. avium complex.

Altered Mental Status in HIV-Positive Patients

Altered mental status is a common presenting symptom in critically ill HIV-infected patients and results from both infectious and noninfectious etiologies. The following factors can help narrow the differential diagnosis: level of CD4 cell count, status of virologic suppression, toxoplasma serology, and ART regimen and timeline (Table 34.1).

While any infection may result in an altered sensorium, dangerous infections of the central nervous system (CNS) include meningitis (bacterial, cryptococcal, tuberculous, syphilitic), viral encephalitis (Cytomegalovirus [CMV], herpes simplex virus [HSV]), or parenchymal lesions including parasitic infection (toxoplasmosis) and brain abscess (bacterial, fungal). All patients with CD4 cell counts <200 cells/mm³ and focal findings should undergo a CT head with intravenous contrast to evaluate for presence of cerebral toxoplasmosis (characterized by ring-enhancing lesions on CT imaging), CNS lymphoma (usually single lesion), and progressive multifocal leukoencephalopathy (plaques in the white matter). Following head imaging, lumbar puncture should be performed to evaluate for bacterial and fungal meningitis or more indolent CNS processes such as syphilitic and tuberculous meningitis.

Noninfectious etiologies in HIV-infected patients with mental status changes include primary CNS lymphoma, HIV-associated dementia, toxins or medication-side effects (e.g., efavirenz), IRIS, and metabolic encephalopathy.

INFECTIONS IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AND FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION

For patients with hematologic malignancies, the primary malignancy dictates the immune defect and pathogen susceptibilities. For example, patients with acute lymphoblastic leukemia have more profound cellular defects than those with acute myeloid leukemia. Multiple myeloma is associated with a reduced humoral immunity. Chronic lymphocytic leukemia is characterized by a prolonged course of T-cell and antibody deficiency. Chemotherapy for hematologic malignancies is uniformly myelosuppressive, resulting in profound neutropenia, which increases susceptibility to bacterial and fungal pathogens. Among chemotherapeutic agents, daunorubicin and cytarabine can produce severe, prolonged neutropenia, while fludarabine and alemtuzumab decrease the T- (especially CD4 cells) and B-cell function.³⁸

For HSCT patients, the preparative regimen for transplantation determines the level of immune suppression. Myeloablative regimens completely suppress the host bone marrow, resulting in profound immune compromise; nonmyeloablative regimens are less suppressive. Posttransplant hematopoietic immune recovery follows a predictable sequence: pre-engraftment (0–1 month), early postengraftment (1 to 3 months) with gradual return of the host’s humoral response, and late postengraftment (>3 months) during which cellular immunity returns. In some patients, cellular immune defects may persist 1 to 2 years posttransplant. If graft versus host disease (GVHD) ensues, prolonged and aggressive immune suppression will be required, increasing the risk of infections.

Febrile Neutropenia

Neutropenia is defined as an absolute neutrophil count (ANC) < 1,500 cells/mm³; severe neutropenia as an ANC < 500 cells/mm³ (ANC = [% Neutrophils + % Bands] × [WBC]/100). Febrile neutropenia is defined as one episode of fever >38.3°C or fever >38°C for ≥1 hour with an absolute neutrophil count (ANC) <500 cells/mm³ or with an expected ANC drop to <500 cells/mm³ within 48 hours. The ANC nadir, duration of neutropenia, and rapidity of decline determine infection risk. Table 34.2 provides criteria for risk-stratifying patients with febrile neutropenia.^39,40

Patients with febrile neutropenia are susceptible to CRBSI, as well as infections that originate in the gastrointestinal tract (most commonly due to bacterial translocation in the setting of mucositis or enterocolitis), lung, kidneys, or soft tissues. The epidemiology of these infections has shifted from gram-negative rods (GNRs) to gram-positive cocci (GPCs, 60% to 75% of positive blood cultures) due to widespread use of antimicrobial prophylaxis that targets GNRs.⁴¹ Common pathogens include coagulase-negative Staphylococcus, S. aureus, Streptococcus spp, Enterococcus, Corynebacterium jeikeium, P. aeruginosa, and Enterobacteriaceae. For patients with enterocolitis, potential pathogens include anaerobes (Clostridium septicum, Clostridium tertium, and Bacillus cereus). Neutropenic patients are also at risk for breakthrough infections, resulting from a gap in the pathogen coverage of prophylactic antibiotics (typically fluoroquinolones) leading to infections with Streptococcus spp and anaerobic spp. Breakthrough infection, for example, from Streptococcus viridans, can rapidly lead to severe sepsis and acute respiratory distress syndrome (ARDS).

Diagnostic Evaluation for Febrile Neutropenia

Laboratory Studies

Although only 30% to 40% of neutropenic fever episodes will prove to have a documented infection,⁴² the clinician must assume an infectious etiology, even when the patient presents with no signs of inflammation (e.g., no meningeal signs, nonproductive cough, no leukocytosis). Table 34.3 highlights diagnostic tests to consider based on the clinical presentation. In a neutropenic host with sepsis, a procalcitonin level may be useful in considering a bacterial etiology (serum cutoff level >0.5 μg/L); it should not be used in localized bacterial or fungal infections, or those due to viral pathogens.^55,56 The serum concentration of procalcitonin peaks at 24 hours after development of fever.

Imaging

CT imaging should be obtained for patients with focal CNS findings and respiratory or abdominal complaints. For patients with lower quadrant abdominal symptoms, typhlitis, also known as neutropenic enterocolitis, should be suspected. Typhlitis is a chemotherapy-related colonic inflammation that leads to bacterial translocation, resulting in diffuse wall edema and perforation. Abdominal CT imaging determines the extent of typhlitis and the presence of local complications.

Treatment of Infection in Patients with HSCT

Antibacterial Therapy

Initial workup and antibiotic administration should occur as soon as possible after presentation to the emergency department. The Infectious Diseases Society of America (IDSA) guidelines recommend an antipseudomonal β-lactam as the initial regimen.³⁹ Cefepime should be avoided, as it is associated with (a) higher all-cause mortality compared with other β-lactams⁵⁷; (b) inferior efficacy compared with piperacillin–tazobactam or carbapenems⁵⁸; and (c) a failure to cover relevant anaerobic pathogens (Bacteroides spp).⁵⁹ If there is a low index of suspicion for multidrug-resistant GNRs (e.g., extended-spectrum beta-lactamase (ESBL) producing organisms), piperacillin–tazobactam is favored over carbapenems, as carbapenems are associated with higher rates of antibiotic- and C. difficile-associated diarrhea.⁵⁸ Among the carbapenems, ertapenem should be avoided as it fails to cover P. aeruginosa. The addition of an aminoglycoside, typically gentamicin, to any of the initial β-lactam regimens may be considered for the neutropenic patient in septic shock until culture results are available that will allow more selective antibiotic choice. Vancomycin should be initiated in HSCT critically ill patients or in those with risk factors for resistant GPC infections (oral mucositis, an indwelling catheter, or colonization with methicillin-resistant S. aureus [MRSA]).

Antifungal Therapy

Antifungals are added for HSCT patients at high risk for candidemia; risk factors include prolonged neutropenia, frequent hospitalizations, a protracted antibiotic course, and the presence of CVC, particularly for the administration of total parenteral nutrition. Antifungals are also indicated if fever persists after 5 days of adequate antimicrobial treatment and negative cultures. To date, there are no compelling studies favoring a specific antifungal agent. The initial use of an echinocandin, however, is now recommended given the rising incidence of azole-resistant Candida spp (Candida glabrata, Candida krusei) and the safer side effect profile of echinocandins compared to liposomal amphotericin.⁶⁰ A suitable alternative would be voriconazole. Both drugs also cover Aspergillus.⁶¹

Generally, CVCs should be replaced upon presentation in severe sepsis or septic shock, given the paucity of symptoms in CRBSI. In the presence of barriers to immediate line exchange, emergency physicians may consider sending blood cultures before antibiotic administration to assess “time-to-positivity” cultures (see CRBSIs in Patients with Solid Tumors).⁴⁷

Adjunctive Therapies

If treatment with colony-stimulating factors has already been initiated, it should be continued. However, a recent meta-analysis did not demonstrate a benefit of colony-stimulating factors in established febrile neutropenia.⁶² Current guidelines suggest their use in high-risk patients: age >65 years, prolonged and severe neutropenia, and septic shock.⁶³ Surgical consultation should be obtained promptly in enterocolitis, biliary sepsis, necrotizing fasciitis, and gynecologic sepsis.

Timing of Infections Following HSCT

Knowledge of the time since transplantation, use of ongoing immune suppression, and previous antimicrobial prophylaxis can help the emergency physician differentiate between noninfectious and infectious etiologies, as well as identify likely pathogens (Fig. 34.1).

Early Postengraftment Period After HSCT

Since the preengraftment period occurs while admitted to the hospital, we will only review the following stages in HSCT that are more relevant to the emergency physician. In the immediate postengraftment period, if no GVHD is encountered, immune suppression is gradually tapered. During this period, respiratory infections predominate. In addition to community-acquired pathogens, HSCT patients are at increased risk from respiratory viruses, including respiratory syncytial virus (RSV), influenza, parainfluenza, and human metapneumovirus.⁶⁴ Prompt diagnosis is essential in initiating respiratory isolation and appropriate antiviral therapy (e.g., ribavirin or oseltamivir). For RSV and influenza, rapid viral antigen tests are recommended, in conjunction with PCR-based detection (Table 34.3). Prophylaxis for CMV with ganciclovir delays the presentation of CMV syndromes. In addition to fever, interstitial pneumonia, and enteritis, CMV reactivation may manifest indirectly (e.g., concurrent infection such as PJP).⁶⁵ If CMV is suspected, PCR testing for quantitative CMV viral load is recommended. Adenovirus infection is also encountered in the early postengraftment period and may result in fulminant hepatitis, pneumonitis, and encephalitis.

Fungal Infections in the Early Postengraftment Period

Hepatosplenic candidiasis (chronic disseminated candidiasis) can develop in patients not receiving antifungal prophylaxis and should be considered in a patient recovering from neutropenia who presents with abdominal pain, fever, and increased alkaline phosphatase. Aspergillosis should be suspected in a clinically stable patient with persistent fevers despite prolonged courses of antibiotics and fluconazole. Typical symptoms include a nonproductive cough and pleuritic chest pain. While fungal blood cultures typically do not improve the diagnostic yield over standard blood cultures, they may be helpful in isolating endemic fungi like Histoplasma or molds such as Fusarium.¹⁹ Aspergillus GM testing in serum and/or bronchoalveolar lavage (BAL) can also help make the diagnosis.⁶⁶ Chest CT imaging in patients with pulmonary Aspergillus typically demonstrates multiple, poorly defined macronodules (>1 cm) with or without “halo,” cavitation, or “air-crescent” sign.⁶⁷ First-line treatment for invasive pulmonary aspergillosis is voriconazole. Other invasive molds (Fusarium, Scedosporium, and agents of mucormycosis) can cause pulmonary, CNS, rhino-orbital, skin, and disseminated disease, and require treatment with liposomal amphotericin.

Late Postengraftment Period After HSCT

Approximately 50% of HSCT patients will develop chronic GVHD and will require prolonged immune suppression. The incidence of bacterial infection decreases substantially in the late posttransplant period, with the exception of infection by encapsulated organisms (e.g., S. pneumoniae) (Fig. 34.1, Table 34.3). Varicella zoster virus (VZV) and PJP also commonly occur in patients receiving corticosteroids for GVHD. Without trimethoprim–sulfamethoxazole (TMP–SMX) prophylaxis, patients are at risk for Nocardia and Toxoplasma infection. Failure of TMP–SMX prophylaxis also can occur (Table 34.3).

INFECTIONS IN PATIENTS WITH SOLID TUMORS

Immune Defect in Patients with Solid Tumors

While at a lower overall risk for infection than those with hematologic malignancies, patients with solid tumors are at risk from infections due to tumor-related immune dysfunction (e.g., mucocutaneous barrier disruption, cellular or humoral deficiencies) or treatment-related immune deficiency resulting from chemotherapy, radiation, or other immune-modulating therapy. Advanced age, malnutrition, comorbid conditions (e.g., chronic obstructive pulmonary disease [COPD]), and frequent health care exposures also increase infection risk.

Catheter-Related Blood Stream Infections in Patients with Solid Tumors

CVCs are essential for the administration of chemotherapeutic agents, but may result in CRBSIs. Local inflammatory changes (e.g., warmth, erythema, or purulent exudate) are unreliable (sensitivity <3%); confirmation with a “time-to-positivity” microbiologic culture, simultaneously drawn from a peripheral site and the CVC, is recommended.⁶⁸ The “time-to-positivity” diagnosis is established either quantitatively by a greater than threefold bacterial colony-forming unit (CFU) yield from the catheter versus the peripheral culture or temporally by catheter culture positivity ≤120 minutes before peripheral culture.^47,48 Typical infecting organisms include coagulase-negative Staphylococcus (31%), S. aureus (20%) with increasing rates of methicillin resistance, Candida (9%), and enterococci (9%) with increasing rates of vancomycin resistance.^46,69

Treatment of CRBSIs

Antibiotic Therapy

Antibiotic therapy should include vancomycin or daptomycin, and, in the presence of neutropenic fever and/or severe illness, an antipseudomonal β-lactam, such as a carbapenem (recommended if the patient has a history of ESBL infection).⁷⁰ Based on risk factors for candidemia, empiric treatment may also include an echinocandin.

Catheter Management

Per the IDSA guidelines, long-term CVCs should be removed in the setting of infection with S. aureus, P. aeruginosa, or Candida. However, in the presence of alternative organisms (coagulase-negative S. aureus, Enterococcus) and in the absence of severe sepsis or complicating tunnel or exit-site infection, a trial of antibiotic lock therapy (ALT) and systemic antibiotics may allow for catheter salvage.^70,71

Neutropenic Fever in Patients with Solid Tumors

In patients with solid tumors, repeated chemotherapy cycles lead to milder and briefer periods of neutropenia, compared to those with hematologic malignancies. Patients with solid tumors have a lower incidence of fungal infections, including Candida and Aspergillus, compared to patients with hematologic malignancies.

Corticosteroid Use and Risk of Opportunistic Infections in Patients with Solid Tumors

Prolonged corticosteroid use is common among solid tumor patients, particularly those with CNS lesions, increasing the risk for opportunistic infections including oropharyngeal candidiasis, Nocardia, Legionella, MTB, Aspergillus, endemic fungi, and P. jirovecii. Pneumocystis pneumonia occurs in <2% of non-HIV, solid tumor patients and is associated with daily prednisone doses (or corticosteroid equivalent) >15 mg for 4 weeks’ duration.^72,73

Diagnosis of PJP in HIV-Negative Patients with Solid Tumors

Due to a decreased P. jiroveci burden in HIV-Negative patients, the diagnostic yield of induced sputum, even with indirect fluorescent antibody (IFA) staining, is low. Recommended initial screening tests include (1–3)-β-d-glucan, PCR-based assays, and high-resolution chest CT imaging evaluating for ground-glass opacities.^74–76 BAL is the gold standard for obtaining diagnostic samples and should be performed in patients with a high clinical suspicion for PJP.⁷⁷

PJP Treatment in HIV-Negative Patients with Solid Tumors

TMP–SMX is the treatment of choice for non–HIV-infected PJP patients. Despite limited evidence in HIV-negative patients, adjunctive corticosteroids (prednisone 40 mg q12h) are recommended in patients with moderate to severe PJP characterized by PaO₂ ≤ 70 mm Hg on ambient air.

Sepsis in Patients with Solid Tumors

Sepsis is a common cause for ICU admission in patients with solid tumors, particularly in the presence of neutropenia caused by respiratory, blood stream, abdominal, and urinary infections. Although these patients do benefit from ICU admission, it is important to note that common prognostic models, including APACHE II or III and the Simplified Acute Physiology Score (SAPS) II, generally underestimate hospital mortality in cancer patients.⁷⁸ In patients with advanced cancer, preferences regarding the extent of therapeutic intervention(s) should be elicited early in their ICU course.

GENERAL CONSIDERATIONS BY TYPE OF SOLID TUMOR

Infections in nonneutropenic cancer patients include community-acquired and nosocomial infections with specific predilections by the type of malignancy (Table 34.4).

Lung Cancer

Pneumonia occurs in up to 24% of patients with lung cancer; 27% of these are postobstructive.⁷⁹ Postobstructive pneumonias are generally polymicrobial; however, there is an increasing incidence of S. aureus and enteric GNR infections due to nosocomial exposures. Antimicrobial treatment should include staphylococcal, anaerobic, and GNR coverage (e.g., vancomycin + piperacillin–tazobactam) to minimize progression to lung abscess or empyema.⁸⁰

Breast Cancer

Patients with breast cancer are at risk for postoperative skin and soft tissue infections (incidence of 4% to 12%). Lymphedema can also cause delayed episodes of streptococcal cellulitis.^81,82 Antimicrobial treatment should include vancomycin, with consideration of antipseudomonal coverage for those with recent chemotherapy or neutropenia. Ultrasound evaluation for an underlying fluid collection should be considered if there is no clinical improvement within 72 hours of antibiotic treatment.

Gastrointestinal Cancer

Persons with gastrointestinal cancers are at risk for bowel obstruction and postsurgical complications, including anastomotic leaks, intra-abdominal abscesses, and peritonitis. Anaerobes (Bacteroides, Clostridium) are common copathogens. Antimicrobial treatment should include broad-spectrum GNR and anaerobic coverage (e.g., piperacillin–tazobactam or a carbapenem). Empiric coverage of Candida with an echinocandin is also recommended. When infectious collections are recognized, percutaneous or surgical drainage (source control) should be initiated within 12 hours.

Genitourinary Cancer

Genitourinary cancer patients have lower rates of infection (<5%); infections in this group are often related to urinary obstruction and/or diversion. Antimicrobial treatment should include coverage of GNRs, including ESBL organisms and vancomycin-resistant enterococci in those with risk factors (urinary procedures, uncontrolled diabetes, colonization with VRE). Urine cultures obtained from ileal conduit are rarely useful. These patients also may experience postsurgical wound infections, ranging from localized cellulitis to extensive infections resulting in pyometra and tuboovarian, intra-abdominal, or pelvic abscesses.

Head and Neck Cancer

For patients with head and neck cancers, wound infections secondary to loss of the protective oral mucosa barrier and subsequent oral anaerobic flora contamination commonly occur (6% to 20% incidence).⁸³ Management includes antimicrobials against oral flora and, where indicated, surgical drainage, which provides diagnostic culture and source control. Pneumonia, from oropharyngeal aspiration, remains a leading cause of death and should be tested for with routine chest radiography.⁸⁴

Infections in Patients after Solid Organ Transplantation

Immune Defect in Patients After SOT

For SOT recipients, intensified immune suppression has improved survival by reducing rejection, but it also increased the risk for infectious complications. Immune suppression may be divided into discrete phases: induction (high-dose corticosteroids ± antilymphocyte antibodies/IL-2 receptor antibodies), maintenance (corticosteroids, antimetabolites, calcineurin inhibitors), and treatment for episodes of rejection (high-dose corticosteroids, plasmapheresis, antilymphocyte antibodies). During the maintenance phase, immune suppression is gradually tapered; however, continued high levels may be required for transplanted organs with increased environmental exposure, such as the small bowel and lung. Despite continued high level of immune suppression, small bowel and lung recipients still experience the highest rates of acute rejection during the first year (70% and 30%, respectively).^85,86 Treatment for acute rejection greatly increases the risk for infection. Plasmapheresis, for example, removes antibodies, increasing the risk for encapsulated bacterial infections. Lymphocyte-depleting therapies result in prolonged B- and T-cell defects, increasing the risk for viral and fungal infections. In general, SOT patients are rarely neutropenic, unless they are receiving chemotherapy for posttransplant lymphoproliferative disease.

Timeline of Infections in SOT

As is the case with patients post-HSCT, knowledge of the timing since transplantation, intensity of immune suppression, and prophylaxis will allow clinicians to differentiate among likely infectious pathogens for solid organ recipients (Fig. 34.2).⁸⁷ Typical prophylaxis includes TMP–SMX against P. jirovecii, Nocardia, Listeria, and Toxoplasma and valganciclovir against CMV and HSV. Lung transplant patients often receive antimold prophylaxis with itraconazole or voriconazole.

Related posts:

Extracorporeal Membrane Oxygenation Sickle Cell Disease Transfusion Therapy The Central Venous and Pulmonary Artery Catheter Pancreatitis Subarachnoid and Intracerebral Hemorrhage